GHENT, Belgium--(BUSINESS WIRE)--AlgoNomics NV, the immunoprofiling company, announced today that it raised 1.5 million euro (about 2.0 million USD) to further accelerate the development of its in vitro screening platform that expands the company’s existing immunogenicity screening services and tools. The patented Epibase® screening tool is currently widely applied for the immunogenicity screening and optimization of biotherapeutics, such as therapeutic antibodies, biosimilars and vaccines.
